|
US10130697B2
(en)
|
2010-03-23 |
2018-11-20 |
Wisconsin Alumni Research Foundation (Warf) |
Vaccines comprising mutant attenuated influenza viruses
|
|
ES2655051T3
(es)
|
2011-08-26 |
2018-02-16 |
Wisconsin Alumni Research Foundation |
Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas
|
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
WO2015196150A2
(en)
|
2014-06-20 |
2015-12-23 |
Wisconsin Alumni Research Foundation (Warf) |
Mutations that confer genetic stability to additional genes in influenza viruses
|
|
TW201628649A
(zh)
|
2014-10-09 |
2016-08-16 |
再生元醫藥公司 |
減少醫藥調配物中微可見顆粒之方法
|
|
TWI710573B
(zh)
|
2015-01-26 |
2020-11-21 |
美商再生元醫藥公司 |
抗伊波拉病毒醣蛋白之人類抗體
|
|
TWI870789B
(zh)
|
2015-08-04 |
2025-01-21 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
|
CN109477074B
(zh)
|
2016-02-19 |
2023-01-24 |
威斯康星旧生研究基金会 |
用于疫苗开发的改进的乙型流感病毒复制
|
|
US11542332B2
(en)
|
2016-03-26 |
2023-01-03 |
Bioatla, Inc. |
Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
US20200148750A1
(en)
|
2016-07-21 |
2020-05-14 |
Emory University |
Ebola Virus Antibodies and Binding Agents Derived Therefrom
|
|
KR20230041834A
(ko)
|
2016-08-16 |
2023-03-24 |
리제너론 파아마슈티컬스, 인크. |
혼합물로부터 개별 항체들을 정량하는 방법
|
|
EP3504328A1
(en)
|
2016-08-24 |
2019-07-03 |
Regeneron Pharmaceuticals, Inc. |
Host cell protein modification
|
|
CN119492842A
(zh)
|
2016-10-25 |
2025-02-21 |
里珍纳龙药品有限公司 |
用于色谱数据分析的方法和系统
|
|
CN113512111B
(zh)
*
|
2017-03-10 |
2023-08-15 |
北京天广实生物技术股份有限公司 |
抗埃博拉病毒单克隆抗体、其制备方法及用途
|
|
BR112020000127A2
(pt)
|
2017-07-06 |
2020-07-07 |
Regeneron Pharmaceuticals, Inc. |
método para selecionar um hidrolisado de soja, e, glicoproteína
|
|
US12162925B2
(en)
*
|
2017-09-15 |
2024-12-10 |
The Wistar Institute Of Anatomy And Biology |
DNA-encoded monoclonal antibodies targeting the Ebolavirus glycoprotein
|
|
CN118416215A
(zh)
|
2017-09-19 |
2024-08-02 |
里珍纳龙药品有限公司 |
减少粒子形成的方法以及由其形成的组合物
|
|
WO2019084310A1
(en)
|
2017-10-25 |
2019-05-02 |
Yoshihiro Kawaoka |
HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION
|
|
BR112020010615A2
(pt)
|
2017-12-22 |
2020-10-27 |
Regeneron Pharmaceuticals, Inc. |
produto farmacêutico proteico, método e sistema para caracterizar impurezas de produto farmacêutico proteico e de fármaco de baixo peso molecular, método para produzir um anticorpo, anticorpo, e, usos do método e do sistema
|
|
RU2686630C1
(ru)
*
|
2017-12-22 |
2019-04-29 |
федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации |
Штаммы гибридных клеток животных Mus. Musculus - продуценты моноклональных антител к белку GP вируса Эбола (subtype Zaire) и моноклональные антитела к белку GP вируса Эбола (subtype Zaire)
|
|
EP3724223A1
(en)
*
|
2018-01-02 |
2020-10-21 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
|
MX2020008095A
(es)
|
2018-01-31 |
2020-09-24 |
Regeneron Pharma |
Sistemas y métodos para caracterizar variantes de tamaño y carga de impurezas de productos farmacológicos.
|
|
WO2019152607A1
(en)
*
|
2018-01-31 |
2019-08-08 |
The Wistar Institute Of Anatomy And Biology |
Nucleic acid antibody constructs for use against ebola virus
|
|
TWI786265B
(zh)
|
2018-02-02 |
2022-12-11 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
|
KR20200127979A
(ko)
|
2018-02-28 |
2020-11-11 |
리제너론 파마슈티칼스 인코포레이티드 |
바이러스 오염물질을 확인하기 위한 시스템 및 방법
|
|
CN108373500A
(zh)
*
|
2018-03-12 |
2018-08-07 |
中国科学院微生物研究所 |
一种热稳定性埃博拉治疗性抗体的制备及应用
|
|
US12259355B2
(en)
|
2018-03-19 |
2025-03-25 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
US12253490B2
(en)
|
2018-03-19 |
2025-03-18 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
CA3246952A1
(en)
|
2018-03-19 |
2025-10-31 |
Regeneron Pharmaceuticals, Inc. |
Microchip capillary electrophoresis assays and reagents
|
|
WO2019190931A1
(en)
*
|
2018-03-26 |
2019-10-03 |
Regeneron Pharmaceuticals, Inc. |
Anti-pfrh5 antibodies and antigen-binding fragments thereof
|
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
TWI853823B
(zh)
|
2018-07-02 |
2024-09-01 |
美商里珍納龍藥品有限公司 |
自混合物製備多肽之系統及方法
|
|
WO2020014443A1
(en)
*
|
2018-07-12 |
2020-01-16 |
Vanderbilt University |
Pan-ebolavirus neutralizing human antibodies and methods of use therefor
|
|
JP7783047B2
(ja)
|
2018-08-07 |
2025-12-09 |
ウィスコンシン アルムニ リサーチ ファンデイション |
組換えの生物学的に封じ込められたフィロウイルスワクチン
|
|
EP3840780A1
(en)
|
2018-08-20 |
2021-06-30 |
Wisconsin Alumni Research Foundation |
Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (ha) protein
|
|
CN120795059A
(zh)
|
2018-08-27 |
2025-10-17 |
瑞泽恩制药公司 |
拉曼光谱在下游纯化中的应用
|
|
US11754569B2
(en)
|
2018-08-30 |
2023-09-12 |
Regeneron Pharmaceuticals, Inc. |
Methods for characterizing protein complexes
|
|
CN111138527B
(zh)
*
|
2018-11-06 |
2021-07-30 |
中国人民解放军军事科学院军事医学研究院 |
抗埃博拉病毒糖蛋白gp1亚基的单克隆抗体4f1及应用
|
|
CN111138526B
(zh)
*
|
2018-11-06 |
2021-07-30 |
中国人民解放军军事科学院军事医学研究院 |
一种抗埃博拉病毒糖蛋白gp2亚基的单克隆抗体2g1及应用
|
|
CN111138531B
(zh)
*
|
2018-11-06 |
2021-07-30 |
中国人民解放军军事科学院军事医学研究院 |
特异结合于ebov的gp1亚基的单克隆抗体8f9及应用
|
|
CN111138528B
(zh)
*
|
2018-11-06 |
2021-07-30 |
中国人民解放军军事科学院军事医学研究院 |
特异性结合于埃博拉病毒糖蛋白聚糖帽的单克隆抗体5a8
|
|
PL3857237T3
(pl)
|
2019-01-16 |
2023-07-10 |
Regeneron Pharmaceuticals, Inc. |
Sposoby charakteryzowania mostka disiarczkowego
|
|
WO2020163804A1
(en)
|
2019-02-08 |
2020-08-13 |
Wisconsin Alumni Research Foundation (Warf) |
Humanized cell line
|
|
EP3934620A1
(en)
|
2019-03-05 |
2022-01-12 |
Regeneron Pharmaceuticals, Inc. |
Human serum albumin in formulations
|
|
CN114929269A
(zh)
|
2019-05-01 |
2022-08-19 |
威斯康星校友研究基金会(Warf) |
用于疫苗开发的改进的流感病毒复制
|
|
AU2020275406A1
(en)
|
2019-05-13 |
2021-11-18 |
Regeneron Pharmaceuticals, Inc. |
Improved competitive ligand binding assays
|
|
JP7627911B2
(ja)
|
2019-08-27 |
2025-02-07 |
ウィスコンシン アルムニ リサーチ ファンデイション |
卵内複製のための安定化されたｈａを持つ組換えインフルエンザウイルス
|
|
US12297451B1
(en)
|
2019-10-25 |
2025-05-13 |
Regeneron Pharmaceuticals, Inc. |
Cell culture medium
|
|
JP6761889B1
(ja)
|
2019-11-11 |
2020-09-30 |
株式会社Ｇｓｐエンタープライズ |
抗ヒトＣｒｉｐｔｏ−１抗体
|
|
MY207613A
(en)
|
2019-11-25 |
2025-03-06 |
Regeneron Pharma |
Sustained release formulations using non-aqueous emulsions
|
|
GB201917480D0
(en)
*
|
2019-11-29 |
2020-01-15 |
Univ Oxford Innovation Ltd |
Antibodies
|
|
US11835527B2
(en)
|
2020-01-21 |
2023-12-05 |
Regeneron Pharmaceuticals, Inc. |
Deglycosylation methods for electrophoresis of glycosylated proteins
|
|
EP4093415A1
(en)
|
2020-01-24 |
2022-11-30 |
Wisconsin Alumni Research Foundation (WARF) |
Recombinant influenza viruses with stabilized na
|
|
KR20210095781A
(ko)
|
2020-01-24 |
2021-08-03 |
주식회사 에이프릴바이오 |
항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
|
|
CN115243718A
(zh)
|
2020-01-24 |
2022-10-25 |
瑞泽恩制药公司 |
稳定的抗体制剂
|
|
WO2021173753A1
(en)
|
2020-02-26 |
2021-09-02 |
Vir Biotechnology, Inc. |
Antibodies against sars-cov-2 and methods of using the same
|
|
US12290562B2
(en)
|
2020-03-25 |
2025-05-06 |
Wisconsin Alumni Research Foundation (Warf) |
Recombinant multivalent influenza viruses
|
|
US12605459B2
(en)
|
2020-07-13 |
2026-04-21 |
Regeneron Pharmaceuticals, Inc. |
Protein-drug conjugates comprising camptothecin analogs and methods of use thereof
|
|
IL300828A
(en)
|
2020-08-31 |
2023-04-01 |
Regeneron Pharma |
Asparagine feeding strategies to improve cell culture performance and reduce asparagine sequence variants
|
|
WO2022074630A1
(en)
*
|
2020-10-09 |
2022-04-14 |
Auxilla Pharmaceuticals And Research Llp |
Liquid oral suspension of favipiravir
|
|
MX2023006077A
(es)
|
2020-11-25 |
2023-06-06 |
Regeneron Pharma |
Formulaciones de liberacion sostenida mediante emulsificacion por membrana no acuosa.
|
|
US12350374B2
(en)
|
2020-12-17 |
2025-07-08 |
Regeneron Pharmaceuticals, Inc. |
Fabrication of protein-encapsulating microgels
|
|
EP4274608A4
(en)
*
|
2021-01-05 |
2025-07-09 |
Immunome Inc |
ANTIBODY COCKTAIL AGAINST SARS-CoV-2 SPIKE PROTEIN
|
|
TW202233827A
(zh)
|
2021-01-20 |
2022-09-01 |
美商再生元醫藥公司 |
改良細胞培養中蛋白質效價的方法
|
|
AR125585A1
(es)
|
2021-03-03 |
2023-08-02 |
Regeneron Pharma |
Sistemas y métodos para cuantificar y modificar la viscosidad de proteínas
|
|
BR112023024984A2
(pt)
|
2021-06-01 |
2024-02-20 |
Regeneron Pharma |
Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit
|
|
TW202326138A
(zh)
|
2021-09-08 |
2023-07-01 |
美商再生元醫藥公司 |
用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
|
|
CA3232463A1
(en)
|
2021-09-20 |
2023-03-23 |
Philip Mellors |
Methods of controlling antibody heterogeneity
|
|
JP2024538673A
(ja)
|
2021-10-07 |
2024-10-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ｐＨモデリング及び制御のシステム及び方法
|
|
KR20240090312A
(ko)
|
2021-10-07 |
2024-06-21 |
리제너론 파아마슈티컬스, 인크. |
Ph 미터 보정 및 교정
|
|
MX2024005090A
(es)
|
2021-10-26 |
2024-07-19 |
Regeneron Pharma |
Sistemas y metodos para generar agua de laboratorio y distribuir agua de laboratorio a diferentes temperaturas.
|
|
CA3242639A1
(en)
|
2022-01-14 |
2023-07-20 |
Regeneron Pharmaceuticals, Inc. |
Verrucarin A derivatives and their antibody-drug conjugates
|
|
US20240245779A1
(en)
|
2023-01-25 |
2024-07-25 |
Regeneron Pharmaceuticals, Inc. |
Methods of modeling liquid protein composition stability
|
|
WO2024158961A1
(en)
|
2023-01-25 |
2024-08-02 |
Regeneron Pharmaceuticals, Inc. |
Mass spectrometry-based characterization of antibodies co-expressed in vivo
|
|
WO2024163708A1
(en)
|
2023-02-01 |
2024-08-08 |
Regeneron Pharmaceuticals, Inc. |
Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
|
|
US20240280551A1
(en)
|
2023-02-22 |
2024-08-22 |
Regeneron Pharmaceuticals, Inc. |
System suitability parameters and column aging
|
|
TW202508625A
(zh)
|
2023-05-01 |
2025-03-01 |
美商再生元醫藥公司 |
使用苯酚或苯甲醇之多劑量抗體藥物產品
|
|
CN121925272A
(zh)
|
2023-09-29 |
2026-04-24 |
瑞泽恩制药公司 |
利用受控成核进行冻干
|
|
WO2025085594A1
(en)
|
2023-10-18 |
2025-04-24 |
Regeneron Pharmaceuticals, Inc. |
Rapid purification of monoclonal antibody from in-process upstream cell culture material
|
|
AU2024373307A1
(en)
|
2023-11-02 |
2026-05-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing lipase activity using stress
|
|
WO2025166281A1
(en)
|
2024-02-01 |
2025-08-07 |
Regeneron Pharmaceuticals, Inc. |
Platform for charge-detection mass spectrometry analysis of aavs
|
|
WO2025175164A1
(en)
|
2024-02-16 |
2025-08-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
|
|
WO2025194043A1
(en)
|
2024-03-15 |
2025-09-18 |
Regeneron Pharmaceuticals, Inc. |
Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
|
|
WO2026025028A1
(en)
|
2024-07-26 |
2026-01-29 |
Regeneron Pharmaceuticals, Inc. |
Methods of making ultra-high concentrated protein formulations using lyophilization
|
|
CN120943942A
(zh)
*
|
2024-09-12 |
2025-11-14 |
南京诺唯赞生物科技股份有限公司 |
特异性结合hpv的抗体
|
|
WO2026060350A1
(en)
|
2024-09-13 |
2026-03-19 |
Regeneron Pharmaceuticals, Inc. |
Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods
|
|
WO2026076201A2
(en)
|
2024-10-03 |
2026-04-09 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools
|
|
WO2026080597A1
(en)
|
2024-10-08 |
2026-04-16 |
Regeneron Pharmaceuticals, Inc. |
Sustained delivery of biologics and non-aqueous manufacture of same
|
|
CN119462912B
(zh)
*
|
2025-01-15 |
2025-08-19 |
中国人民解放军军事科学院军事医学研究院 |
抗埃博拉病毒vp40蛋白的纳米抗体及在病毒检测中的应用
|